OPEN END TURBO OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 06:35:05 2024-05-21 am EDT | ||
| 13.56 EUR / 13.86 EUR | +3.16% |
|
| Current month | -28.05% | ||
| 1 month | -28.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 13.56 | +2.03% |
| 24-05-20 | 13.29 | -1.26% |
| 24-05-17 | 13.46 | -3.17% |
| 24-05-16 | 13.9 | -2.25% |
| 24-05-15 | 14.22 | -5.33% |
Delayed Quote Börse Stuttgart
Last update May 21, 2024 at 06:11 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB9183 |
| ISIN | DE000JB91831 |
| Date issued | 2023-12-27 |
| Strike | 590.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 17.43 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.79 € |
|---|---|
| Lowest since issue | 13.29 € |
| Spread | 0.5 € |
| Spread % | 3.56% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.9
USD
Average target price
462.8
USD
Spread / Average Target
+3.80%
- Stock Market
- Certificates
- Certificat
